Literature DB >> 10792961

All-trans-retinoic acid decreases vein graft intimal hyperplasia and matrix metalloproteinase activity in vivo.

C D Leville1, M S Dassow, G R Seabrook, J M Jean-Claude, J B Towne, R A Cambria.   

Abstract

BACKGROUND: Development of vein graft intimal hyperplasia has been associated with increased activity of matrix metalloproteinases (MMPs). All-trans-retinoic acid (atRA) decreases expression and activity of MMPs in tissue culture and has decreased intimal hyperplasia following arterial balloon catheter injury. We examined the effect of oral administration of atRA on intimal hyperplasia and MMP expression in an animal model of vein bypass grafting.
MATERIALS AND METHODS: Interposition jugular vein bypass grafts were placed in the carotid artery of New Zealand white rabbits. Animals received either atRA (10 mg/kg/day) or vehicle (corn oil) for a period of 2 weeks. Retinoic acid serum levels were determined by HPLC. Intimal and medial areas were measured using morphometric analysis of perfusion-fixed vein graft specimens, and intimal thickness was calculated using circumferential measurements. Expression of MMP-2, MMP-9, and TIMP-1 in vein grafts and unoperated control veins was determined using Northern analysis, and proteolytic activity was determined using substrate gel zymography.
RESULTS: Animals treated with atRA had significantly elevated serum levels of this compound and its metabolites. A decrease in intimal to medial ratio was noted after 28 days in vein grafts from treated animals (0.63 vs 0.88, P < 0.01), and a decrease in calculated intimal thickness was noted at 7 and 28 days. Expression of MMP-2 was decreased in treated animals 7 days following surgery, and expression of both MMP-2 and MMP-9 was decreased at 28 days. A decrease in proteolytic activity was noted on zymography at 68 kDa, 7 and 28 days following surgery in vein grafts from animals treated with atRA, corresponding with a decrease in the active form of MMP-2. Increased expression of TIMP-1 was noted in vein grafts from both the treated and the control groups, 7 and 28 days following graft placement.
CONCLUSIONS: Oral administration of all-trans-retinoic acid resulted in decreased intimal hyperplasia in an animal model of vein bypass grafting. This was associated with decreased expression and activity of MMP-2 in treated animals. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792961     DOI: 10.1006/jsre.2000.5887

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  4 in total

1.  13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy.

Authors:  Judith Adams; Eva Kiss; Ana B V Arroyo; Mahnaz Bonrouhi; Qiang Sun; Zhen Li; Norbert Gretz; Anna Schnitger; Christos C Zouboulis; Manfred Wiesel; Jürgen Wagner; Peter J Nelson; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

2.  Inhibiting intimal hyperplasia in prosthetic vascular grafts via immobilized all-trans retinoic acid.

Authors:  Elaine K Gregory; Antonio Webb; Janet M Vercammen; Megan E Kelly; Banu Akar; Robert van Lith; Edward M Bahnson; Wulin Jiang; Guillermo A Ameer; Melina R Kibbe
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

3.  Retinoid-induced expression and activity of an immediate early tumor suppressor gene in vascular smooth muscle cells.

Authors:  Jeffrey W Streb; Xiaochun Long; Ting-Hein Lee; Qiang Sun; Chad M Kitchen; Mary A Georger; Orazio J Slivano; William S Blaner; Daniel W Carr; Irwin H Gelman; Joseph M Miano
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

4.  Histopathological evaluation of a retinoic acid eluting stent in a rabbit iliac artery model.

Authors:  Ioanna Samara; Christos S Katsouras; Arsen Semertzioglou; Athanassios Vratimos; Amalia I Moula; Constantinos A Dimitriou; Michail Theofanis; Triantafyllia Papadimitropoulou; Vasileios Bouratzis; Georgia Karanasiou; Dimitrios Fotiadis; Lampros K Michalis; Anargyros N Moulas
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.